Reviewing Yield10 Bioscience (YTEN) and Curis (CRIS)
Curis (NASDAQ: CRIS) and Yield10 Bioscience (NASDAQ:YTEN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitabiliy and risk.
Valuation & Earnings
This table compares Curis and Yield10 Bioscience’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Curis||$7.93 million||32.27||-$46.08 million||($0.47)||-3.79|
|Yield10 Bioscience||$1.33 million||12.36||-$8.65 million||($0.44)||-13.11|
Yield10 Bioscience has higher revenue, but lower earnings than Curis. Yield10 Bioscience is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Curis has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Yield10 Bioscience has a beta of 3.57, meaning that its share price is 257% more volatile than the S&P 500.
This is a summary of recent ratings for Curis and Yield10 Bioscience, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Curis currently has a consensus target price of $6.67, indicating a potential upside of 274.53%. Given Curis’ higher possible upside, research analysts clearly believe Curis is more favorable than Yield10 Bioscience.
Institutional & Insider Ownership
49.5% of Curis shares are held by institutional investors. Comparatively, 13.4% of Yield10 Bioscience shares are held by institutional investors. 6.1% of Curis shares are held by company insiders. Comparatively, 13.0% of Yield10 Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Curis and Yield10 Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Yield10 Bioscience beats Curis on 7 of the 12 factors compared between the two stocks.
Curis Company Profile
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
Yield10 Bioscience Company Profile
Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.